welcome first quarter result conference call operator instruction please note conference record turn conference host mark vice president investor relation thank begin mark vice president investor good afternoon thank join today call chairman chief executive officer chief financial officer close regular trade release first quarter financial result today call management result include press release accompany financial statement remain time please note management make forward look statement base estimate assumption projection statement include limit financial guidance expectation longer term growth opportunity regulatory approval clinical trial litigation reimbursement competitive matter foreign currency fluctuation statement speak date make undertake obligation update today additionally statement involve risk uncertainty include limit associate pandemic could cause actual result differ materially information concern factor could cause difference important product safety information find press release annual report file available company website finally quick reminder term underlie adjust management refer financial measure otherwise refer result reconciliation number mention call include today press release like turn call comment chairman chief executive mark anniversary year impact pandemic financial result like briefly reflect current environment longer term priority company also like touch response pandemic effort better support patient employee community recall sale dramatically impact last week procedure fell disruption year later extraordinarily difficult global crisis encourage sign recovery although recognize many people still struggle around world sale growth quarter better expect across product line although expect pandemic impact global healthcare system base environment exit quarter continue confidence positive outlook continue believe important growth year teen sale growth highlight importance treat structural heart patient even pandemic also anticipate meaningful progress expand large appreciate underserved transcatheter opportunity recently achieve several important milestone mention four last week transcatheter aortic valve replacement receive approval initiate pivotal trial patient suffer moderate aortic stenosis also earlier month receive approval begin treat patient surgical risk transcatheter mitral tricuspid therapy please announce first patient recently treat next generation transcatheter mitral replacement system also initiate pivotal trial transcatheter tricuspid replacement look beyond remain confident long term strategy pipeline innovative therapy patient focus culture drive motivate employee around world every target breakthrough therapy create significant value patient health system enable strong organic sale growth exceptional shareholder return despite disruption continue invest aggressively future growth reminder third research development investment today focus generate robust body guideline change clinical evidence although clinical study slow pandemic dedicate clinician partner eager accelerate important research regulator also support address impact pandemic impact clinical study finally want provide perspective maintain focus create long term value navigate pandemic last year continue invest people infrastructure time widespread uncertainty impact many family across globe prioritize protect employee grow enhance employee benefit reward performance protect incentive also move ahead expand research production facility around world adjust agreement support hospital navigate additionally provide extra support community employee live work fact recently convert facility mass vaccination site support community million people company headquarter company expect position even stronger able help patient ever world emerge pandemic turn first quarter result report billion sale quarter constant currency basis year recall guidance assume sale would line first quarter last year largely unaffected please sale improve quarter progress first quarter global sale million underlie basis ultra platform remain differentiate complication rate ease significant potential length stay efficiency average sell price stable estimate global procedure growth comparable growth sale flat fourth quarter year result estimate overall procedure growth comparable consistent guidance earn call late stress global healthcare system winter month encourage however procedure grow hospitalization decrease vaccination increase quarter small medium size center play valuable role serve patient quarter continue activate center quarter throughout pandemic demonstrate clear interest many smaller center provide state care structural heart patient outside first quarter estimate procedure grow double digit year year basis growth comparable although strong start slow vaccination progress outside provide uncertainty remainder year underlie growth versus prior year single digit range growth country lower adoption rate outpace country therapy establish although center prepare treat patient patient flow disrupt regional lockdown uncertainty among patient urgency disease sale growth country strong aortic stenosis remain immensely undertreated disease remain focus increase availability therapy previously note receive approval earlier month patient surgical risk anticipate increase treatment rate reimbursement approve later year addition geographic expansion therapy remain dedicate pursue indication expansion groundbreaking early trial focus patient severe aortic stenosis without recognize symptom meet current guideline valve replacement expect enrollment increase participate site motivate complete enrollment trial year also please report receive approval pivotal trial moderate patient expect enrollment begin later year base recent trial learn think benign precursor severe aortic stenosis actually associate higher rate morbidity mortality previously recognize thus believe future treatment option patient separately last week receive mark approval begin treat patient previously repair replace valve position look ahead upcoming virtual meet next month expect long term follow data registry late break clinical trial result risk bicuspid patient summary base strength first quarter confidence underlie sale grow range expect continue near term relate regional disruption normalize second half year remain confident large global opportunity exceed billion imply compound annual growth rate double digit turn five pivotal trial across differentiate portfolio technology support patient suffer tricuspid mitral valve disorder quarter progress enrollment three pivotal trial continue expect approval patient late next year expect first commercial approval system also begin treat patient pivotal trial accordance breakthrough pathway designation trial evaluate safety effectiveness tricuspid valve replacement system patient severe tricuspid regurgitation addition first patient recently treat next generation transcatheter mitral replacement system call study study evaluate safety performance design advance treatment patient mitral regurgitation profile valve deliver french transfemoral delivery system believe platform replacement strategy strongly position leader treat underserved patient expand body clinical evidence look forward present meaningful data across portfolio upcoming virtual medical meet include multiple late break presentation include longer term outcome transcatheter mitral repair trial first report outcome tricuspid replacement study turn result first quarter global sale million drive continue adoption system activation center across assume diminish relate impact expect ramp sale throughout year remain confident sale guidance million advance commercialization stay focus physician train procedural success patient outcome adoption favorable real world clinical outcome remain driver transform treatment summary make meaningful progress toward milestone continue estimate global opportunity reach approximately billion remain commit transform treatment patient mitral tricuspid valve disease around world surgical structural heart first quarter global sale million increase underlie basis prior year despite soft start associate encourage improvement across region course quarter notably growth lift premium product improve decline case enable hospital resume treat surgical structural heart patient remain encourage steady global adoption tissue valve include continue adoption aortic surgical valve anticipate adoption bolster five year data commence clinical trial present recent meet society thoracic surgeon demonstrate excellent durability tissue technology please first quarter initiate sale sale also continue gain traction first aortic tissue valve conduit patient require replacement valve route ascend aorta critical unmet patient need finally please announce receive regulatory approval reimbursement valve mitral valve incorporate newest tissue technology yesterday perform first commercial case differentiate innovation summary confidence full year underlie sale growth high single digit range surgical structural heart drive market adoption premium technology continue believe current billion surgical structural heart market grow single digit critical care first quarter sale million increase underlie basis drive increase sale technology operate room intensive care unit order increase hospital capital spend begin show sign recovery demand product high risk surgery remain strong invasive finger cuff elective procedure also recover near level disposable pressure monitor device remain demand elevate hospitalization begin continue expect full year underlie sale growth high single digit range critical care remain excite pipeline critical care innovation continue shift focus smart recovery technology design help clinician make better decision patient turn call corporate vice president chief financial thank encourage start year despite still impact global healthcare system first quarter able post positive year year sale growth across product line region advance therapy help patient globally total sale grow year year underlie basis better flat growth expect give guidance first quarter back stronger expect sale performance fell bottom line result adjust earn share higher first quarter improvement sale performance quarter choppy exit quarter stronger position give continue confidence outlook balance year macro condition remain variable across geography project total sale second quarter grow sequentially billion billion result adjust earn share business continue rebound impact expect sale strengthen expense grow travel clinical trial ramp maintain previous sale guidance range total expect sale billion billion billion billion approximately million surgical structural heart million million critical care million million base first quarter earn raise full year adjust earn share guidance cover additional detail result first quarter adjust gross profit margin compare period last year reduction drive negative impact foreign exchange incremental associate respond partially offset improve manufacture efficiency continue expect adjust gross profit margin sell general administrative expense first quarter million sale compare million prior year increase primarily drive strengthen currency primarily euro personnel relate partially offset reduce travel spend result mention earlier anticipate spend increase year travel restriction subside resume normalize operate environment continue expect full year percentage sale exclude special item similar level research development expense quarter grow million sale increase primarily result continue investment transcatheter innovation full year continue expect percentage sale range similar level invest develop technology generate evidence expand indication turn report rate quarter rate include basis point benefit account stock base compensation continue expect full year rate exclude special item include estimate benefit percentage point stock base compensation account foreign exchange rate increase first quarter report sale growth basis point million compare prior year current rate expect approximate million positive impact full year sale compare rate negatively impact first quarter gross profit margin basis point compare prior year relative guidance rate positively impact first quarter free cash flow first quarter million define cash flow operate activity million capital spend million turn call back finish update balance sheet share repurchase activity continue maintain strong flexible balance sheet approximately billion cash investment march repurchase million share million first quarter approximately million remain share repurchase authorization plan continue execute strategy offset dilution incentive stock compensation opportunistically reduce share outstanding time average share outstanding first quarter million approximately million prior quarter continue expect average dilute share outstanding million million back chairman chief executive remain confident long term patient focus strategy innovation pipeline serve many patient suffer structural heart disease never stop invest people innovative technology growth capacity company expect position even stronger position help patient ever world fully emerge pandemic turn call back mark mark vice president investor ready take question order allow broad participation please limit number question plus follow additional question please reenter queue management answer many participant possible remainder call